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JOURNAL OF HEPATOLOGYReply to: ‘‘The role of CD147 in liver injury: The truth is in the details’’To the Editor:
We greatly appreciate the letter by McLennan et al., which dis-
cusses our recently published article on the role of HAb18G/
CD147 promoting liver ﬁbrosis through activation of hepatic stel-
late cells (HSCs) [1].
In a chronically injured liver, caused by hepatitis B virus
(HBV), hepatitis C virus (HCV), alcohol or other factors, HSCs
are activated by inﬂammation mediators and differentiate into
myoﬁbroblasts, which play an important role in the development
of liver ﬁbrosis and cirrhosis. In China, HBV causes more cases of
liver cirrhosis than HCV, therefore our research interest focused
on HBV-related liver cirrhosis in our article [1]. The published
article by Shackel et al. using array analysis compared gene
expression of HCV-associated cirrhosis with autoimmune hepati-
tis-associated cirrhosis, showing a marked difference in the apop-
tosis-associated gene proﬁle, reﬂecting the fact that different
pathogens lead to different gene expression proﬁles.
However no data were shown in HBV-associated cirrhosis [2].
The antibody HAb18, for immunohistochemistry (IHC) of
human liver cirrhosis tissue, mentioned in our article, has already
been used for years in our laboratory, is qualiﬁed for Western
blot, IHC, immunoﬂuorescent staining, and has been granted
international patents (Patent Numbers: PCT/CN03/00188 and
PCT/CN2002/000356) [3,4]. The fragment F(ab0)2 of HAb18
labeled with 131I, registered as Licartin, has been approved for
the treatment of hepatocellular carcinoma (HCC) by the China
State Food and Drug Administration (Registration No.
S20050039) [5]. HAb18 combines with the Ig-C2 domain of iso-
form Basigin-2, which is the most predominant splice variant,
encoding the well-known EMMPRIN/CD147, but not with isoform
Basigin-3 [6,7].
Our previous IHC with commercial mouse anti-human CD147
antibody (NovoCastra) showed immunostaining in the tumor
compartment, but not in the stromal compartment, in HCC tis-
sues, which is consistent with our HAb18 staining in cirrhotic tis-
sues, where HAb18G/CD147 was absent in the ﬁbrous septa area
[8,1]. In the mouse liver ﬁbrosis model, CD147 expression in acti-
vated HSCs was shown with a commercial rat anti-mouse CD147
antibody (Abcam ab34016) by co-localization with alpha-smooth
muscle actin (a-SMA) in Disse’s space [1]. In our previous study
we showed that HAb18G/CD147 was expressed in hepatocytes
of cirrhotic and HCC tissues, consistent with Shackel’s paper
[9,2]. The a-SMA-positive cells represent a heterogeneous popu-
lation, including activated resident ﬁbroblasts, activated HSCs,Journal of Hepatology 20bone marrow-derived mesenchymal cells and ﬁbrocytes, hepato-
cytes or biliary epithelium-derived ﬁbroblasts by epithelial-mes-
enchymal transition, which means that not all of the a-SMA-
positive cells are derived from HSCs. Therefore, we identiﬁed
HSCs by reaction with a-SMA and their localization in the peris-
inusoidal space. McLennan et al. showed a positive staining of a-
SMA by immunoﬂuorescence in ﬁbrotic septa while no immuno-
reaction with a-SMA was observed in the perisinusoidal space
(Fig. 1D). Importantly, ﬁbrous septa composed of collagen have
a strong autoﬂuorescence, the speciﬁc ﬂuorescence is suggested
to be identiﬁed by blank and isotype controls. In Fig. 1C of the
McLennan’s study, the co-localization of CD147 with CK-18 was
observed in hepatocytes, but no CK-18 expression was observed
in some CD147 positive cells detected by green ﬂuorescence.
LX-2 cell line was originally isolated with property of a-SMA
expression detected by immunoﬂuorescence [10]. We also
observed a weak immunoﬂuorescent signal of a-SMA expression
in our work. However, we did not observe a detectable level of a-
SMA protein expression by Western blot, but mRNA expression
was detected by real-time PCR in untreated LX-2 cells. Stable
transfection with the CD147 gene in LX-2 cells induced a notable
a-SMA expression [1]. This may be due to a different detection
sensitivity and different sources of primary and secondary
antibodies.
In summary, we have reasons to believe that the HAb18 anti-
body used by us works properly and that the conclusions drawn
from these experiments are valid.
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To the Editor:
Ogawa et al. reported interesting and important ﬁndings, based
on a large prospective cohort, regarding the effect of combination
therapy with peginterferon and ribavirin on the incidence of
hepatocellular carcinoma (HCC) [1]. They reported lower inci-
dence of HCC after treatment in patients with transient virologi-
cal response (TVR, deﬁned as relapse or breakthrough), as well as
in patients with sustained virological response (SVR), relative to
patients with non-virological response (NVR). The suppressive
effect of this antiviral therapy on the development of HCC in
patients with SVR has been established by several reports and
can be explained by the eradication of hepatitis C virus (HCV),
resulting in the release of inﬂammation and improvement of liver
ﬁbrosis [2]. However, it is unclear why the incidence of HCC after
treatment was also lower in patients with TVR than in those with
NVR, despite the persistence of viremia after treatment. Ogawa
et al. attributed this observation to the preventive effect of com-
plete HCV suppression during therapy on the development of
HCC.
Previously reported viral and host factors that are strongly
associated with response to antiviral therapy with peginterferon
and ribavirin [3,4] may also be associated with the pathogenesis
of HCC. Amino acid substitutions in the HCV core region, a viral
factor reportedly associated with the response to peginterferon
and ribavirin therapy in patients with HCV genotype 1b [3] (i.e.,
the vast majority of subjects in the study by Ogawa et al.), are also
associated with the development of HCC [5]. Regarding host fac-
tors associated with the response to combination therapy [4],
genetic polymorphisms near the IL28B gene are reportedly asso-
ciated with hepatic steatosis [6] and interact with amino acid
substitutions in the HCV core region [5,7]. Both hepatic steatosis
and amino acid substitutions in the HCV core region are associ-
ated with the development of HCC [5,8]. In addition, amino acid
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substitutions in the HCV core region are reportedly associated
with the development of HCC, even in patients who achieved
SVR [9]. Ogawa et al. reported, without providing detailed data,
a higher incidence of HCC in patients bearing the non-TT geno-
type of rs8099917 near the IL28B gene, which is unfavorable to
response to the combination therapy; this observation is also
consistent with our previous report [10].
These results suggest that differences in HCC incidence based
on the outcome of antiviral combination therapy are mainly
attributable to these viral and host factors. It is possible that Oga-
wa et al. simply classiﬁed patients based on the likelihood of
developing HCC upon observing the response to the combination
therapy (i.e., TVR and NVR). It would be interesting if the authors
were to analyze the incidence of HCC in relation to the outcome
of combination therapy based on these host and viral factors. In
addition, it would be interesting to investigate genetic polymor-
phisms near the IL28B gene and amino acid substitutions at res-
idue 70 of the HCV core region, in the 13 patients who developed
HCC despite the achievement of SVR.
Given the existence of factors associated with both therapeu-
tic response and incidence of HCC, one should be cautious in
drawing the conclusion that lower incidence of HCC in patients
with TVR, relative to those with NVR, actually reﬂects the ‘‘sup-
pressive effect’’ of peginterferon and ribavirin combination ther-
apy on hepatocarcinogenesis.
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